Microaneurysm Reflectivity as a Prognostic Biomarker for Intravitreal Treatment Response in Diabetic Retinopathy.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 41617122.
- Also identified by DOI 10.1016/j.ajo.2026.01.027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To investigate whether baseline reflectivity patterns of diabetic microaneurysms (MAs) on spectral-domain optical coherence tomography (SD-OCT) predict treatment response in diabetic macular edema (DME). Retrospective clinical cohort study. Sixty-six patients with treatment-naive DME were analyzed. All microaneurysms within the central 3 mm ETDRS area were identified and classified based on internal reflectivity on SD-OCT. Patients were categorized into 2 phenotypic groups based on the predominant reflectivity pattern: predominantly hyperreflective phenotype (>50% hyperreflective MAs) or predominantly hyporeflective phenotype (>50% hyporeflective MAs). Patients received intravitreal anti-VEGF therapy or dexamethasone implants over 12 months. The primary outcome was complete intraretinal fluid resolution at 12-month follow-up. Thirty-nine patients (59.1%) were classified as hyperreflective phenotype and 27 (40.9%) as hyporeflective phenotype at baseline. Complete fluid resolution was achieved in 20 of 39 hyperreflective phenotype patients (51.3%) compared to 2 of 27 hyporeflective phenotype patients (7.4%, P < .001). Multivariate logistic regression confirmed phenotype classification as the only independent predictor of treatment response (OR 13.50, 95% CI 2.87-63.51, p < .001). Microaneurysm reflectivity phenotype on SD-OCT may serve as a useful predictor of treatment response in DME. Hyperreflective phenotype demonstrated significantly higher rates of fluid resolution compared to hyporeflective phenotype, independent of patient characteristics and treatment modality.
Medical subject headings
- Diabetic Retinopathy
- Angiogenesis Inhibitors
- Microaneurysm
- Macular Edema
- Dexamethasone